Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200468 | 1.00 | MAPK1 (0.49) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL25329639 | 0.98 | MAPK1 (0.47) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL247351 | 0.83 | PTGS2 (0.57) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL15836535 | 0.83 | KMT2A (0.44) | MAPK1ALDH1A1TDP1KMT2ACES2 | |
| SCHEMBL17355729 | 0.82 | PTPN1 (0.53) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL6200625 | 0.82 | MAPK1 (0.47) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL28691323 | 0.82 | MAPK1 (0.47) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL6194083 | 0.82 | MAPK1 (0.47) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL868843 | 0.82 | ACHE (0.59) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 | |
| SCHEMBL156400 | 0.82 | CYP4F2 (0.51) | MAPK1KDM4EPTGS2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20180198069-A1 | P-Doping Cross-Linking Of Organic Hole Transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-101486638-B | Preparation of 2,3-difluorophenylacetic acid | ZHEJIANG YONGTAI TECHNOLOGY CO LTD | 2013-02-20 | — | — | CN | claimed |
| CN-101837303-A | Novel nickel catalyst and preparation method and application thereof | SHANGHAI WANSHUO CHEMICAL CO LTD | 2010-09-22 | — | — | CN | claimed |
| EP-4531919-A1 | METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY | Elixiron Immunotherapeutics (Hong Kong) Limited (HK) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240408106-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-12-12 | — | — | US | disclosed |
| US-20240376118-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-11-14 | — | — | US | disclosed |
| US-20240317734-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-09-26 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2005056530-A1 | BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2005-06-23 | — | — | WO | disclosed |
| EP-0950669-B1 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM & HAAS (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1150962-A1 | PROCESS FOR THE PREPARATION OF 6-(PERFLUOROALKYL)URACIL COMPOUNDS FROM CARBAMATE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6306991-B1 | TWO PART COATING COMPOSITION WITH TWO CONTAINERS, OXIDATIVE POLYMERS WITH CROSSLINKABLE FUNCTIONAL GROUPS | ROHM AND HAAS COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6149977-A | CONTACTING THE OXIDATIVE POLYMER WITH A CATALYTIC AMOUNT OF AN OXIDIZING ENZYME, SUCH AS HORSERADISH PEROXIDASE. | ROHM AND HAAS COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000049003-A1 | PROCESS FOR THE PREPARATION OF 6-(PERFLUOROALKYL)URACIL COMPOUNDS FROM CARBAMATE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 2000-08-24 | — | — | WO | disclosed |
| EP-0950669-A2 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM AND HAAS COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376118-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MAPK1 4357/4885KDM4E 669/4885PTGS2 4413/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MAPK1 4357/4885KDM4E 669/4885PTGS2 4413/4885 |
| US-20240408106-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MAPK1 4357/4885KDM4E 669/4885PTGS2 4413/4885 |
| US-20240317734-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MAPK1 4357/4885KDM4E 669/4885PTGS2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.